M2 stage Pharmacological screening in silico and GRN analyses to boost ASCs and reverse aging
CDD · Stage M2 · 6 mois Bac+4 RESTORE U1301 INSERM UMR5070 CNRS · Toulouse (France) standard M2
Date de prise de poste : 1 janvier 2025
Mots-Clés
aging single cell GRN
Description
Mesenchymal stem cells (MSCs) are important for muscle regeneration, but the mechanisms behind this are not fully understood. Recently, our group showed that MSCs from subcutaneous adipose tissue (ScAT) migrate to injured muscle to promote regeneration in mice. To further understand this process, we performed scRNA-seq using tagged ScAT in wild-type mice to track MSCs as they move from ScAT to injured muscle and identified the sub-populations involved. Our goal is to force differentiation of ASCs into the phenotype of this sub-population. To this aim, we propose to perform several single cell analyses on our data to infer gene regulatory network (GRN) at play and perform pharmacologial screening in Silico using bioinformatic tools. In addition, we want to study alterations of ASCs with aging (transcriptomics analyses) and use a similar approach to reverse aging-induced alterations. This research will provide invaluable insights into the mechanisms of aging of MSCs, which becomes impaired during aging and leads to muscle atrophy and decreased mobility in older individuals. It will also serve as a foundation for future work on MSCs and their potential use in cell therapy.
R and/or Python, bash
5 to 6 months, flexible starting date
Candidature
Procédure :
Date limite : 28 février 2025
Contacts
xavier contreras
xaNOSPAMvier.contreras@inserm.fr
Offre publiée le 29 octobre 2024, affichage jusqu'au 28 février 2025